Document Detail


The Use of a Single Von Willebrand Factor-Containing, Plasma-Derived FVIII Product in Hemophilia a Immune Tolerance Induction - U.S. Experience.
MedLine Citation:
PMID:  21883884     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background: Inhibitors are a serious complication for patients with severe hemophilia A. Immune tolerance induction (ITI) is the primary method for eradicating these inhibitors. The role of type of concentrate and in particular the use of von Willebrand factor-containing, plasma-derived factor VIII (VWF/pd-FVIII) concentrate in primary or rescue ITI remains unclear. Objectives: To report retrospective data collection on the use of a single VWF/pd-FVIII concentrate in primary and rescue ITI. Methods: Retrospective chart review of hemophilia A inhibitor patients at 11 US institutions who received VWF/pd-FVIII concentrate in primary or rescue ITI. Results: Primary ITI was carried out in 8 inhibitor patients with a 75% complete and partial success. Secondary ITI was carried out in 25 inhibitor patients with 52% attaining complete or partial success. Conclusions: This report represents the largest group of primarily pediatric, high-titer inhibitor patients treated with a single VWF/pd-FVIII concentrate. It adds retrospective data to the use of VWF-containing plasma-derived factor VIII concentrate in primary and rescue ITI particularly in those patients with characteristics for poor response to ITI.
Authors:
M Kurth; J Puetz; P Kouides; J Sanders; C Sexauer; J Bernstein; R Gruppo; M Manco-Johnson; E J Neufeld; N Rodriguez; B Wicklund; D Quon; L Aledort
Related Documents :
3751504 - Thymectomy in late-onset myasthenia gravis.
9477134 - Soluble cd95 in the serum of patients with low and intermediate grade malignant lymphom...
1783534 - Submaximal nerve stimulation with the datex relaxograph nmt monitor in myasthenia gravis.
8015044 - Ultrasonography: not useful in detecting susceptibility to malignant hyperthermia.
6791484 - Verapamil therapy in variant angina pectoris refractory to nitrates.
18651514 - How to manage patients with aortic stenosis?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-28
Journal Detail:
Title:  Journal of thrombosis and haemostasis : JTH     Volume:  -     ISSN:  1538-7836     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-9-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101170508     Medline TA:  J Thromb Haemost     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 International Society on Thrombosis and Haemostasis.
Affiliation:
Department of Pediatrics, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN Department of Pediatrics, Cardinal Glennon Children's Medical Center, St. Louis MO Department of Medicine, University of Rochester Medical Center, Rochester, NY Department of Pediatrics, Cook Children's Hospital, Fort Worth, TX Department of Pediatrics, Oklahoma University Health Science Center, Oklahoma City, OK Children's Center for Cancer and Blood Diseases, Las Vegas, NV Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH Department of Pediatrics, University of Colorado and Health Sciences Center, Children's Hospital Colorado, Aurora, CO Department of Pediatrics, Children's Hospital of Boston, Boston, MA Department of Pediatrics, University of Texas-Texas Medical Center, Houston, TX Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO Department of Medicine, Orthapedic Hospital, Los Angeles, CA Department of Medicine, Mount Sinai Medical Center, New York City, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Muscle-directed Gene Therapy for Hemophilia B with More Efficient and Less Immunogenic AAV Vectors.
Next Document:  A Functional Variant in the Thrombospondin-1 Gene and the Risk of Small for Gestational Age Infants.